Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC
Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC
Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups
Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease
The RxPONDER trial and its impact on best clinical practice
OncoAlert and ecancer round up: SABCS 2021
Clinical utility of molecular tumour profiling in breast cancer